摘要
哺乳动物雷帕霉素靶蛋白(mammalian target of rapamycin,mTOR)是调控免疫细胞与肾实质细胞增殖、分化、凋亡、自噬和衰老等细胞生物学事件的关键分子,在胚肾发育以及移植肾排异反应、糖尿病肾病和多囊肾病、狼疮肾炎、移植性肾病等疾病发生发展中具有重要作用。雷帕霉素是mTORC1特异性抑制剂,通过调节T淋巴细胞活化增殖抑制免疫排异反应而改善移植肾功能。动物实验中雷帕霉素通过保护足细胞、抑制肾间质炎症与纤维化等病变以延缓糖尿病肾病、膜性肾病等慢性肾脏病肾功能丢失;促进囊壁衬里细胞凋亡,阻抑多囊肾囊肿形成与增大以保护肾功能。雷帕霉素类似物已作为治疗转移性肾细胞癌的二线药物。
Mammalian target of rapamycin （mTOR） is a key molecule that regulates proliferation, differentiation, apoptosis, autophagy, and senescence of both immune cells and renal parenchyma ceils, playing an important role in embryonic kidney development, renal graft rejection, diabetic nephropathy, polyeystie kidney disease, and other kidney diseases. Rapamycin is a specific inhibitor of mTORC1 that prevents immune rejection and improves graft kidney function through regulating the activation and proliferation of T lymphocytes. In animal experiments, rapamycin can delay the loss of renal functions by protecting podoeytes and inhibiting renal interstitial inflammation and fibrosis in diabetic nephropathy, membranous nephropathy, and other chronic kidney diseases. Rapamyein also protects renal functions through promoting apoptosis of cyst lining cells and restraining cyst formation in polycystic kidney disease. Rapamycin analogues have already been used as second-line drugs to treat metastatic renal cell carcinoma.
出处
《中华肾病研究电子杂志》
2014年第4期11-15,共5页
Chinese Journal of Kidney Disease Investigation（Electronic Edition）
